Cranberries - Vaccinium macrocarpon

PreclinicalSmall molecule

Cranberries - Vaccinium macrocarpon is one of 7 small molecule programs targeting Premature rupture of membranes. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Premature Rupture of MembranesActive, not recruiting

Premature Rupture of MembranesPreclinical

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Premature Rupture of Membranes

#DrugCompanyPhaseTrials

Cytotec

Pfizer

Approved

4 2

Imdur

Cervidil

1 4

Pitocin

RRetrophin

Preclinical

3 5

Epsom Salt

FFresenius Kabi USA, LLC

Preclinical

1 6

Antibiotics

MMelinta Therapeutics, Inc.

Preclinical

1 7

Cranberries - Vaccinium macrocarpon

HHadassah Medical Organization

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Premature rupture of membranes1 trial

The Use of Cranberries in Women With Preterm Premature Rupture of Membranes

Unknown status·HHadassah Medical Organization·N/A·NCT00247104·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cranberries - Vaccinium macrocarpon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cranberries - Vaccinium macrocarpon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cranberries - Vaccinium macrocarpon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hadassah Medical Organization company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHadassah Medical Organization

Cranberries - Vaccinium macrocarpon

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Premature rupture of membranes1 trial

References

Drug Info

Quick Facts

Related News